Want to see BDRX full AI Analyst Report?
BDRX Stock Chart & Stats
$2.33
$0.02(0.46%)
At close: 4:00 PM EST
$2.33
$0.02(0.46%)
Day’s Range― - ―
52-Week Range$2.45 - $66.50
Previous CloseN/A
Volume6.04K
Average Volume (3M)260.97K
Market Cap
$1.17M
Enterprise Value-$6.77M
Total Cash (Recent Filing)$8.52M
Total Debt (Recent Filing)$60.89K
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Sep 11, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-536.25
Shares Outstanding828,923
10 Day Avg. Volume685,915
30 Day Avg. Volume260,967
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.08
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market Cap-5.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.95
Enterprise Value/Ebitda0.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$7.66K
Bulls Say, Bears Say
Bulls Say
Late-stage Clinical Program (eRapa Phase 3)A registrational Phase 3 program with FDA/EMA engagement is a durable de-risking milestone: positive Phase 3 data or approvable endpoints would create a clear path to commercialization, partnering, or licensing, materially changing the company's revenue prospects and strategic optionality over months.
Low Leverage And Strengthened Equity BaseVery low debt and a meaningful equity base provide financial flexibility to fund clinical programs without heavy interest burden. This balance-sheet conservatism reduces bankruptcy risk and preserves strategic choices for partnering or non-dilutive capital over the medium term.
Improved IP, Partnerships And Non-dilutive FundingA granted U.S. patent and in-licensing from an established company strengthen technological differentiation and pipeline breadth. Grants and targeted financing reduce near-term cash pressure and make the company a more attractive partner, improving long-term program viability and licensing potential.
Bears Say
Zero Product RevenueThe firm remains pre-commercial with no product revenue, meaning operations rely entirely on financing and partnerships. Absent successful late-stage readouts, there is no durable internal cash generation to fund R&D or operations, creating long-term sustainability risk until commercialization.
Ongoing Cash Burn And Negative Free Cash FlowContinued negative operating and free cash flow indicates sustained funding needs. Even with year-over-year improvement, negative FCF forces recurring capital raises or dilution and constrains the timing and scale of clinical programs, limiting strategic autonomy across the next several quarters.
Governance And Capital-structure DisruptionA large reverse split, deferred shares and an adjourned AGM signal shareholder engagement and capital-structure risks. These actions can complicate investor rights, reduce liquidity and deter some institutional investors or partners, creating lasting governance and market-access headwinds.
Biodexa Pharmaceuticals News
BDRX FAQ
What was Biodexa Pharmaceuticals’s price range in the past 12 months?
Biodexa Pharmaceuticals lowest stock price was $2.45 and its highest was $66.50 in the past 12 months.
What is Biodexa Pharmaceuticals’s market cap?
Biodexa Pharmaceuticals’s market cap is $1.17M.
When is Biodexa Pharmaceuticals’s upcoming earnings report date?
Biodexa Pharmaceuticals’s upcoming earnings report date is Sep 11, 2026 which is in 63 days.
How were Biodexa Pharmaceuticals’s earnings last quarter?
Biodexa Pharmaceuticals released its earnings results on Mar 27, 2026. The company reported -$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.001.
Is Biodexa Pharmaceuticals overvalued?
According to Wall Street analysts Biodexa Pharmaceuticals’s price is currently Overvalued.
Does Biodexa Pharmaceuticals pay dividends?
Biodexa Pharmaceuticals does not currently pay dividends.
What is Biodexa Pharmaceuticals’s EPS estimate?
Biodexa Pharmaceuticals’s EPS estimate is 0.
How many shares outstanding does Biodexa Pharmaceuticals have?
Biodexa Pharmaceuticals has 828,923 shares outstanding.
What happened to Biodexa Pharmaceuticals’s price movement after its last earnings report?
Biodexa Pharmaceuticals reported an EPS of -$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.514%.
Which hedge fund is a major shareholder of Biodexa Pharmaceuticals?
Currently, no hedge funds are holding shares in BDRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
Technical Analysis
―
Indaptus Therapeutics
―
InMed Pharmaceuticals
―
Enveric Biosciences
―
CNS Pharmaceuticals
―
Ownership Overview
―
Insiders
―
Mutual Funds
34.66% Other Institutional Investors
65.34% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---